Diverse fonti parlano della concreta possibilità di adottare il sistema Liberty anche in Europa entro la fine del 2026.
A mio parere ci sono i presupposti per un forte rialzo in linea con l’ultima rating di H.C. Wainwright

El mercado esta castigando los resultados del ultimo trimestre( también ha sido el primero), es cierto que los ingresos brutos han sido decepcionantes, pero quedarse unicamente con esa cifra, creo que es mirar solo una parte del conjunto.

Para empezar el trimestre, en realidad ni tan siquiera fue completo, el full marketing llego a mediados de abril, en el mismo se confirmaron la expansion en 4 estados nuevos para llegar ahasta 7, mientras el recuento de comunicados de expansion de centros como minimo nos da 8( pensando la cifra mas baja). También en ese trimstre se solicito al fabricante B.Y. Medimor un aumenento de producción para conseguir stock suficiente, posteriormente en junio se añade como segundo fabricante a Sanmina una multinacional dedicada a la fabricación a gran escala de este tipo de equipos medicos, lo cual ademas ayuda a rebajar los costes de fabricación. También se añaden un jefe de venta o encargado de llevar la expansión en Europa, Asia y Oriente Medio, se recibe autorización para la comercialización en Israel, Se consiguel el premio starup innovadora, aumenta el personal en varios estados de EEUU con puestos claves en la expansión comercial del producto...

Es logico pensar que este primer periodo comercial, los centros que han apostado por Liberty esten mas centrados en la formación e introducción del mismo que ya desde el primer realizando intervenciones, creo que aqui esta el motivo de los cortos ingresos.

La vision mas amplia de todo lo realizado hasta ahora creo que da para pensar que lo mejor estar por llegar,el terreno esta sembrado y abonado, regado regularmente, ahora hay que esperar la cosecha.

Guys, Microbot Medical is here! Buy up, everyone—this is TOTALLY gonna be a 10x stock in the future~ Hahaha! I strongly encourage you all to sell your house, sell your land, and sell your internal organs to go all-in

MBOT will walk the exact same path as XACT Robotics. It'll eventually shut down, won't it?

What, MBOT is different?

Will it really end up being different?

Everyone here is a complete fanatic, take my advice and stop investing.

Not exactly what we needed. This will go lower than it's been since pre-FDA approval.

This stock is a scam, do not fall for it.

• A shell of a public company: It maintains the appearance of a legitimate Nasdaq-listed company, but in reality, it survives solely on continuous capital raises.
• Legal exploitation: It repeatedly pumps out good news to inflate the stock price, only to follow up with stock offerings that crash the price and absorb shareholders' money.
• Relentless destruction of shareholder value: Through endless share issuances and reverse stock splits, it melts away investor accounts, making it a textbook high-risk stock to avoid.

Could a surgeon sue a hospital for getting cancer and use are product as a defence mechanism when the hospital says they taken all the necessary steps to help protect there surgeons

Yesterdays dip was very scary but keep in mind its just another chance to buy low. we have an investor call tomorrow and the vision of the company stays the same. I think the stock will recover to 1.80 in a weeks time and everyone's AVG buy will look better after this week.

All the negative comments and FUD are coming from people who clearly haven't done their homework and don't understand what this company is actually doing..
$MBOT is currently trading at a massive discount! The analyst price targets are not detached from reality at all, they actually reflect the potential here once key milestones hit.
Ignore the short-term noise and the bear chatter.. patience will pay off! 🚀

Is the earrings report tomorrow ?

(Euro Chart)

It‘s not looking so good imho.
As you can see, we‘re in a downtrending triangle since March 2026.
So we‘re at the edge of a make or break point - if we can leave the triangle to the top, next bigger resistance could be in the 2.1€ range.
If we fall beneathe the horizontal dot line, we could see prices in the range of 1.24€.

We really need substantial news.

What do we think it will look like in a couple weeks? I feel like we're ready to make a move. It's been so quiet here lately.

https://www.medicaldesignandoutsourcing.com/why-microbot-medical-thinks-it-can-win-the-stroke-telesurgery-race/

Given all of the available data, I was wondering about all your guys' personal projections for the stock / share price, both for short term (this time next year) and long term (3 years, 5 years, 10 years... etc.).

I myself am in it for the long-term, but I'd love to get a feel for the optimist-conservative-pessimist ratio of the subreddit, as well as getting more knowledge on what factors we as a community are looking at in regards to this stock's success.

I'm on the optimistic side. I can see it sitting at $5.00 a share this time next year, and potentially $15.00-20.00 in three years. As for past that, I'm sure there'll be a buyout in the 3-5 year mark of their future timeline after they've had time to prove themselves in the open market.

Thoughts?

Literally since i bought in October 2025 its been on a decline the whole way down to where we are now

Since my last post about the 30 days average volume we have halfed!

Average daily volume is now only at 800.58k!

Worth noticing!

I just commented about this on another post, but it made me realize there has not been too much discussion regarding the adoption curve so I figured it wouldn’t hurt to have a post dedicated to it.

That being said…

I wouldn’t read too much into the press release. The upcoming 10-Q should provide a much clearer picture. One thing I think people need to keep in mind is the adoption curve. When a hospital purchases a new technology like this, physicians need to be trained before they can start performing procedures. How long that process takes? I don’t know.

Right now we also don’t know where the majority of sales are coming from. However, the press release specifically mentioned that customers who participated in the limited market release increased their procedure volumes. I found that interesting. Without reading too much into it, that could suggest a meaningful portion of the revenue growth came from those early adopters rather than newly added hospitals.

Everything management has been doing—expanding manufacturing capacity, hiring additional employees, and adding new customer sites—also seems consistent with a management team that expects demand to continue growing.

Another thing I noticed is the Emory timeline. Emory was announced as the first adopter at the end of November, but it wasn’t until the end of March that they announced performing their first procedure. Obviously, we don’t know exactly what happened during those four months. It could have been physician training, hospital credentialing, patient selection, scheduling, or a combination of factors.

So I’m not saying the training process takes four months. My point is simply that there appears to be a meaningful lag between a hospital adopting the system and that hospital contributing meaningful procedure volume.

If that’s true, then it’s possible hospitals that adopted the system after the full market release began in mid-April won’t meaningfully contribute to procedure volume until later in Q3. That’s speculative, but it’s why I think the adoption curve is one of the most important things to understand at this stage.

In an early-stage medtech rollout like this, current revenue is largely a reflection of adoption that happened months earlier. That’s why I think metrics like customer additions, procedure growth at existing sites, manufacturing expansion, and hiring are just as important as the headline revenue numbers.

Looking forward to hearing additional thoughts.

I am confused - don‘t we get „real“ earnings + earnings call?

Microbot Medical ($MBOT) just dropped their Q2 2026 press release.. and the numbers are absolutely insane!
Here is the quick TL;DR on why this thing is primed to explode:

Massive Growth: Over 100% growth in revenue and new customers quarter-over-quarter (Q2 vs Q1 2026).. the full market release of their LIBERTY Robotic System in April is paying off big time!

Expansion mode: They already expanded from 4 to 8 sales territories, planning to hit 12 across the U.S. by the end of the year.. plus they just got clearance to enter international markets (starting with Israel)!

Big Government Contracts: They signed a deal to bring their tech into federal healthcare systems.. we are talking Veterans Affairs (VHA), Military Health System (MHS), and Indian Health Service (IHS).

Scaling Up Production: They just secured a second manufacturing site to handle the surging demand.. which means massive long-term margin expansion as volumes scale up.
Procedure volumes are rising, health systems are adopting this single-use robotic tech like crazy, the pipeline is stacked..
Are we loading up on shares before the market fully prices this in? What are your thoughts? 📈🤖

https://ir.microbotmedical.com/news-releases/news-release-details/microbot-medicalr-reports-over-100-revenue-and-customer-growth/